The UK and US have established a landmark trade agreement that will maintain no levies on UK pharmaceutical shipments going into the American market.
Agreement Details of the Deal
As part of the deal, the UK has committed to boost funding on drugs through the NHS. This pledge guarantees that tariffs on these vital products will be held at nothing for a period of 36 months.
This development follows earlier statements to hike duties on patented drug imports, with potential rates mentioned reaching double the cost.
"This agreement with the Britain bolsters the global environment for new treatments and introduces much-needed balance to transatlantic medicine commerce," an announcement noted.
Economic Importance
Medicines represent one of the UK's most significant export categories to the United States, which is clearly the primary destination for large British pharmaceutical firms.
Export figures show that in the year leading up to last September, the UK sold medicines valued at over eleven billion pounds to the US. This value made up nearly one-fifth of total UK exports in that timeframe.
"This agreement protects employment, stimulates funding and paves the way for the UK to become a worldwide center for medical research," a minister commented.
Specific British Pledges
The agreement involves several specific commitments from the British government:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it considers new treatments to be unaffordable by 25%.
- Increased NHS Spending: There is a target to increase total public funding on drugs from 0.3% of the national economy to 0.6% over the following ten-year period.
- Rebate Cap: The amount pharmaceutical firms must return to the NHS to control costs will be restricted at fifteen percent. Last year, rebates topped 20%.
Industry Background
The pact follows a protracted row between the drug companies and the UK government over drug pricing and NHS adoption.
This friction were intensified by arguments that American patients were paying a premium for the same drugs than consumers in the Britain and the EU.
Recently, several significant pharmaceutical investments in the UK have been halted or cancelled, while multi-billion-dollar funding commitments have been announced toward US facilities.
The Science Minister acknowledged that the NHS had to spend more on treatments, noting that its budget allocation on drugs had declined as a proportion of its overall budget over the previous ten-year period.
